Xingqi Eye Pharma's SQ-23082 Eye Drops Win NMPA Clinical Trial Approval for Allergic Conjunctivitis Itch
Xingqi Eye Pharmaceutical announced on September 11, 2026, that the company recently received a Drug Clinical Trial Approval Notice issued by the National Medical Products Administration, covering the drug SQ-23082 eye drops.
The eye drops are a Class 2.1 improved new chemical drug developed by the company, and are proposed clinically for the treatment of eye itch associated with allergic conjunctivitis.
The announcement stated that no ophthalmic formulation of this product is currently marketed in China or abroad.
Why this event matters
The event has a measured impact on 1 industry. The strongest current signal is positive for Pharmaceuticals, with intensity 40/100 and 70% confidence over a long term horizon.
Impact figures are analytical estimates that combine direction, intensity, confidence and event importance. They are not investment advice.